Biotech Merger SwanBio Therapeutics recently merged with Spur Therapeutics, expanding its pipeline of genetic medicines. This merger offers potential cross-selling opportunities for new gene therapy candidates.
AMN Gene Therapy SwanBio's gene therapy candidate for adrenomyeloneuropathy (AMN) presents a unique value proposition in the biotechnology space. Highlighting the breakthrough potential of this first-in-class therapy can capture the interest of healthcare providers and patients seeking innovative treatments.
Revenue and Funding With revenue in the range of $0 - 10M and recent funding of $10M, SwanBio has the financial backing to support its growth trajectory. Leveraging this data in sales pitches can instill confidence in potential partners and investors regarding the company's stability and investment potential.
Competitive Analysis Analyzing similar companies like NorthSea Therapeutics and Escient Pharmaceuticals with varying employee counts and revenue benchmarks provides valuable insights into SwanBio's competitive positioning and market differentiation. Understanding the competitive landscape can guide sales strategies for targeted market penetration and competitive advantage.
| SwanBio Therapeutics Email Formats | Percentage |
| FLast@swanbiotx.com | 98% |
| Last@swanbiotx.com | 1% |
| FMLast@swanbiotx.com | 1% |
Biotechnology ResearchPennsylvania, United States11-50 Employees
SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com.
Company Overview
Funding & FinancialsSwanBio Therapeutics has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Oct 04, 2023 in the amount of $10M.
SwanBio Therapeutics's revenue is in the range of $10M
Funding & FinancialsSwanBio Therapeutics has raised a total of $10M of funding over 4 rounds. Their latest funding round was raised on Oct 04, 2023 in the amount of $10M.
SwanBio Therapeutics's revenue is in the range of $10M
1-888-653-2347 
support@leadiq.com